Allspring Global Investments Holdings LLC Sells 250,373 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Allspring Global Investments Holdings LLC reduced its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 87.1% in the 4th quarter, HoldingsChannel reports. The firm owned 37,021 shares of the company’s stock after selling 250,373 shares during the period. Allspring Global Investments Holdings LLC’s holdings in CRISPR Therapeutics were worth $2,318,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its stake in shares of CRISPR Therapeutics by 158.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 3,014,551 shares of the company’s stock worth $183,194,000 after acquiring an additional 1,848,437 shares during the last quarter. ARK Investment Management LLC raised its stake in shares of CRISPR Therapeutics by 19.2% in the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock worth $534,360,000 after acquiring an additional 1,372,986 shares during the last quarter. State Street Corp raised its stake in shares of CRISPR Therapeutics by 228.8% in the second quarter. State Street Corp now owns 1,569,860 shares of the company’s stock worth $95,400,000 after acquiring an additional 1,092,384 shares during the last quarter. BlackRock Inc. raised its stake in shares of CRISPR Therapeutics by 79.2% in the first quarter. BlackRock Inc. now owns 2,278,774 shares of the company’s stock worth $143,038,000 after acquiring an additional 1,007,246 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of CRISPR Therapeutics by 261.4% in the first quarter. Vanguard Group Inc. now owns 1,217,289 shares of the company’s stock worth $76,410,000 after acquiring an additional 880,463 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,913 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total value of $152,408.71. Following the sale, the general counsel now owns 57,371 shares of the company’s stock, valued at $4,570,747.57. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,913 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the sale, the general counsel now directly owns 57,371 shares of the company’s stock, valued at $4,570,747.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 19,582 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the sale, the chief executive officer now directly owns 208,122 shares in the company, valued at $12,468,589.02. The disclosure for this sale can be found here. Insiders have sold a total of 133,992 shares of company stock valued at $9,157,835 over the last 90 days. 4.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Wells Fargo & Company boosted their target price on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 22nd. Mizuho lifted their price target on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Morgan Stanley lifted their price target on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a research report on Monday, February 26th. Chardan Capital lifted their price target on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $90.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, April 11th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, CRISPR Therapeutics has a consensus rating of “Hold” and a consensus price target of $76.29.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $55.05 on Monday. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10. The firm’s 50 day moving average price is $72.96 and its two-hundred day moving average price is $63.52. The firm has a market cap of $4.67 billion, a P/E ratio of -28.09 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.95. The business had revenue of $201.20 million during the quarter, compared to the consensus estimate of $148.72 million. The business’s revenue for the quarter was up 3253.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.41) EPS. On average, sell-side analysts anticipate that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.